The molecular diversity of Luminal A breast tumors

Breast Cancer Research and Treatment

Volumn 141, Issue 3, 2013, Pages 409-420

  Ciriello, Giovanni ^a   Sinha, Rileen ^a   Hoadley, Katherine A ^b   Jacobsen, Anders S ^a   Reva, Boris ^a   Perou, Charles M ^b   Sander, Chris ^a   Schultz, Nikolaus ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Breast cancer genomics; Luminal A breast cancer

Indexed keywords

AURORA A KINASE; AURORA B KINASE; NUCLEAR RECEPTOR COREPRESSOR; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR GATA 3;

AKT1 GENE; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CHROMOSOME 1; CHROMOSOME 16; CHROMOSOME 8; CHROMOSOME ABERRATION; COPY NUMBER VARIATION; GATA3 GENE; GENE; GENOMIC INSTABILITY; GENOMICS; HUMAN; LUMINAL A BREAST TUMOR; MAP3K1 GENE; PIK3CA GENE; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENE DOSAGE; GENE EXPRESSION; GENOMIC INSTABILITY; HUMANS; KAPLAN-MEIER ESTIMATE; MAP KINASE KINASE KINASE 1; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84887068493     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2699-3     Document Type: Article

References (53)

1. Paik S et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817-2826
2. Paik S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726-3734
3. Romond EH et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673-1684
4. Slamon DJ, Romond EH, Perez EA (2006) Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol 4(3 Suppl 7): suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10
5. Perez EA et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29(25):3366-3373
6. Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874
7. Perou CM et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752
8. Parker JS et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160-1167
9. Fan C et al (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355(6):560-569
10. TCGA (2012) Comprehensive molecular portraits of human breast tumors. Nature 490:61-70
11. Ellis MJ et al (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486(7403):353-360
12. Curtis C et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346-352
13. Stephens PJ et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403):400-404
14. Nik-Zainal S et al (2012) The life history of 21 breast cancers. Cell 149(5):994-1007
15. Nik-Zainal S et al (2012) Mutational processes molding the genomes of 21 breast cancers. Cell 149(5):979-993
16. Banerji S et al (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486(7403):405-409
17. Haque R et al (2012) Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev 21(10):1848-1855
18. Chin K et al (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10(6):529-541
19. Russnes HG et al (2010) Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2(38):38ra47
20. Hicks J et al (2006) Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 16(12):1465-1479
21. Cerami E et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401-404
22. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57(1):289-300
23. Olshen AB et al (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5(4):557-572
24. Zhang J, CNTools: Convert segment data into a region by sample matrix to allow for other high level computational analyses. R package (Version 1.6.0.)
25. Gentleman RC et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10):R80
26. R-Development-Core-Team (2010) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
27. Kapp AV, Tibshirani R (2007) Are clusters found in one dataset present in another dataset? Biostatistics 8(1):9-31
28. Dees ND et al (2012) MuSiC: identifying mutational significance in cancer genomes. Genome Res 22:1589-1598
29. Beroukhim R et al (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 104(50):20007-20012
30. Dennis G et al (2003) DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4(5):P3
31. Ciriello G et al (2012) Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 22(2):398-406
32. Flagiello D et al (1998) Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer. Genes Chromosomes Cancer 23(4):300-306
33. Tsuda H et al (1999) der(16)t(1;16)/der(1;16) in breast cancer detected by fluorescence in situ hybridization is an indicator of better patient prognosis. Genes Chromosomes Cancer 24(1):72-77
34. van de Vijver MJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999-2009
35. Whitfield ML et al (2006) Common markers of proliferation. Nat Rev Cancer 6(2):99-106
36. Zhang A et al (2004) Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators. J Biol Chem 279(32):33799-33805
37. Zhang A, Li CW, Chen JD (2007) Characterization of transcriptional regulatory domains of ankyrin repeat cofactor-1. Biochem Biophys Res Commun 358(4):1034-1040
38. Keeton EK, Brown M (2005) Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19(6):1543-1554
39. Cutrupi S et al (2012) Targeting of the adaptor protein Tab 2 as a novel approach to revert tamoxifen resistance in breast cancer cells. Oncogene 31:4353-4361
40. Girault I et al (2003) Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 9(4):1259-1266
41. Green AR et al (2008) The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Breast Cancer Res Treat 110(3):427-437
42. Ellis MJ, Perou CM (2013) The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 3(1):27-34
43. Zardavas D, Baselga J, Piccart M (2013) Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol 10(4):191-210
44. Gautschi O et al (2008) Aurora kinases as anticancer drug targets. Clin Cancer Res 14(6):1639-1648
45. Nishida N et al (2007) High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther 6(4):525-533
46. Dar AA et al (2010) Aurora kinase inhibitors - rising stars in cancer therapeutics? Mol Cancer Ther 9(2):268-278
47. Juric D, Baselga J (2012) Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors. J Clin Oncol 30(8):765-766
48. Small GW et al (2007) Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 67(9):4459-4466
49. Bose R et al (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3(2):224-237
50. Ross JS et al (2013) Relapsed classic E-cadherin (CDH1) mutated invasive lobular breast cancer demonstrates a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res 19:2668-2676
51. Prat A et al (2013) Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 18(2):123-133
52. O'Toole SA et al (2013) Therapeutic targets in triple negative breast cancer. J Clin Pathol 66:530-542
53. Pacheco JM et al (2013) Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res Treat 138(1):281-289